PBM Contracts Should Focus On Net Cost, Not Rebates, Express Scripts Says
Executive Summary
Drug plans should focus on PBMs' abilities to lower overall net cost of prescriptions, rather than try to get a share of manufacturer rebates, Express Scripts Senior VP Thomas Boudreau told a Federal Trade Commission hearing on health care competition June 26 in Washington, D.C
You may also be interested in...
Generics Last? Medco Accused Of Shifting Away From Mature Brands
Medco makes a practice of transferring market share away from brands that are about to lose exclusivity, a False Claims Act suit unsealed June 23 alleges
IG Compliance Guide Will Change PBM Rebate Policies, AdvancePCS Says
The HHS Inspector General's compliance guide for pharmaceutical manufacturers will "push" pharmacy benefit management companies to reform their drug rebate policies, AdvancePCS CEO David Halbert suggested at the SG Cowen health care conference in Boston March 19
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011